Bannerbild German Brest Group - Newsroom

Newsroom der German Breast Group

In unserem Newsroom finden Sie Aktuelles rund um die German Breast Group. Zusätzlich bieten wir Ihnen in diesem Bereich Bildmaterial und Informationen zu unseren Veranstaltungen. Als Überblick unserer Forschungstätigkeiten stehen zudem unsere Annual Scientific Reports hier für Sie zum Download bereit.

 
  • 24.08.2018 ASCO Trending: GeparNuevo

    ASCO Trending: GeparNuevo

    Priming the Immune System: Neoadjuvant Durvalumab Plus Chemotherapy May Be Beneficial in Triple-Negative Breast Cancer

  • 31.07.2018 Paper of the month: BRCA1/2 Mutations and Bevacizumab

    A translational research study performed with samples obtained from a cohort of patients with triple-negative breast cancer (TNBC) enrolled in the neoadjuvant GeparQuinto (GBG 44) study has been published in the Journal of Clinical Oncology.

  • 06.07.2018 Review on Endocrine Therapy in Premenopausal HR+/HER2- Metastatic Breast Cancer

    Unser Review zur Endokrine Therapie in prämenopausale Patientinnen mit Hormone Rezeptor-positivem, HER2-negativem metastasiertem Brust Krebs wurde in The Oncologist publiziert.

  • 30.06.2018 Paper of the month: test predicts the risk of recurrence in luminal breast cancer

    A translational study including samples from two randomized neoadjuvant GBG trials (GeparTrio and GeparQuattro) that aimed to evaluate a novel test (mEPclin) for predicting the risk of distance recurrence after neoadjuvant chemotherapy in patients with residual estrogen receptor (ER)-positive/HER2-negative breast cancer has been published in the Clinical Cancer Research.

  • 04.06.2018 ASCO: GeparNuevo Presentation

    GeparNuevo Results of primary objective were presented at ASCO 2018: Durvalumab increases the pCR rate in TNBC patients.

  • 31.05.2018 Paper of the month: elderly women and neoadjuvant chemotherapy

    A pooled analysis using data from eight GBG trials (GeparDuo, GeparTrio pilot and main, GeparQuattro, AGO-1, PREPARE, TECHNO; GeparQuinto) that aimed to help selecting appropriately the elderly women who would benefit from neoadjuvant chemotherapy has been published in the Oncotarget.

  • 30.04.2018 Paper of the month: survival analysis of the GeparQuinto trial

    We are delighted to inform you that the long-term survival analysis of the neoadjuvant GeparQuinto (GBG 44) phase III trial has been published in the Journal of Clinical Oncology.

  • 30.03.2018 Paper of the month: March 2018

    An analysis of 802 women with triple-negative breast cancer (TNBC) from the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) and GeparSixto (GBG 66) trial that investigated the association between the age at TNBC diagnosis and the presence of pathogenic germline BRCA1/2 mutations has been published in the BMC Cancer.

  • 13.03.2018 ESMO 2019

    ESMO 2019

    ESMO Breast Cancer congress ist taking place in May 2019 in Berlin, Germany.

  • 28.02.2018 Paper of the month: February 2018

    The first results of the BrighTNess trial designed to evaluate the addition of veliparib (a PARP inhibitor) plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) have been published in the The Lancet Oncology.

  • 02.02.2018 Informationsvideo für Patienten

    Prof. Loibl, Leiterin der GBG und Prof. Jackisch, Chefarzt am Sana Klinikum Offenbach sprechen mit einer Patientin über ihre Erfahrungen in einer klinischen Studie.

  • 31.01.2018 Paper of the month: January 2018

    A collaborative translational study that included data from six neoadjuvant GBG trials (GeparDuo, GeparTrio, GeparQuattro, GeparQuinto, GeparSixto and GeparSepto) and investigated the role of tumour-infiltrating lymphocytes (TILs) as a prognostic factor in different subtypes of breast cancer after neoadjuvant therapy has been published in the The Lancet Oncology.

  • 22.01.2018 JCO top-cited

    Unser Paper über PIK3CA-Mutationen ist eines der meistzitierten Paper in JCO.

  • 12.01.2018 Neue Anforderungen für GCP-Nachweise

    Ab Januar 2018 verlangen viele Ethikkommissionen GCP-Nachweise mit neuen Anforderungen.

  • 04.12.2017 Mamma Mia! Patientenkongress in Frankfurt

    Mamma Mia! Patientenkongress am 4. Februar 2018 (Weltkrebstag) im Kap Europa, Frankfurt/M.

  • 17.08.2017 Effect of BRCA1/2 Status on Response to Neoadjuvant Carboplatin in TNBC

    Unser Paper zur Mutationsanalyse im Geparsixto-TNBC-Arm wurde in den ASCO-News besprochen.

  • 05.07.2017 PALOMA-3 Results published

    Palbociclib Combined with Fulvestrant in PremenopausalWomen with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results

  • 13.04.2017 Gewinner des Young Investigator Award

    Gewinner des Young Investigator Award

    Wir gratulieren dem Gewinner des Young Investigator Award 2017, Dr. med. André Hennigs aus Heidelberg

  • 06.04.2017 Erste Ergebnisse der INSEMA-Studie publiziert

    Dier ersten Ergebnisse der Intergroup-Sentinel-Mamma (INSEMA) Studie wurde in der Zeitschrift Geburtshilfe Frauenheilkunde veröffentlicht.

  • 29.03.2017 Buchempfehlung: Babybauch und Chemoglatze

    Buchempfehlung: Babybauch und Chemoglatze

    Die Schwangerschaft – eine Zeit, in der neues Leben beginnt. Doch was passiert, wenn zeitgleich etwas Tödliches im Körper wächst?

Kontakt

GBG Forschungs GmbH

+4961027480-0

+4961027480-440

E-Mail: nfgbgd



GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd